Syncona Share News (SYNC)

Syncona portfolio firm hits 70% remission rate goal in leukaemia trial

(Alliance News) - Syncona Ltd on Friday said portfolio company Autolus Therapeutics PLC achieved the primary endpoint in the clinical trial of its treatment for acute lymphoblastic leukaemia.

Syncona's Autolus leukemia treatment meets trial endpoint

(Sharecast News) - Syncona portfolio company Autolus Therapeutics announced that a phase 2 clinical trial in adult acute lymphoblastic leukemia (ALL) patients has met its primary endpoint at interim analysis.

Syncona investee Achilles continues to progress cancer trials

(Alliance News) - Syncona Ltd on Tuesday noted the continued positive progress in lung cancer trials by its portfolio company.

Syncona's Achilles says cancer treatment shows promise; seals buy

(Alliance News) - Syncona Ltd on Thursday noted a promising safety profile for a cancer therapy concocted by one investee, and separately announced the completion of an acquisition in the retinal gene therapy space.

TOP NEWS: AstraZeneca to buy Neogene for cancer treatment

(Alliance News) - AstraZeneca PLC said it agreed to buy Neogene Therapeutics Inc for the treatment of cancer, as also noted by healthcare company Syncona Ltd on Tuesday.

LONDON MARKET OPEN: Stocks up as protests in China deterred by police

(Alliance News) - The FSTE 100 opened in the green on Tuesday as investors were reassured that civil unrest in China would be short lived amid unyielding action by the authorities.

LONDON BRIEFING: easyJet boasts "record bounce back" as loss narrows

(Alliance News) - Stocks in London were set to open slightly higher on Tuesday as unrest in the world's second largest economy continued.

Syncona net assets rise in half year and outlines 10-year growth plans

(Alliance News) - Syncona Ltd on Thursday said net assets increased in the first half of its financial year, as it outlined plans to grow its net assets to GBP5 billion within the next 10 years.

Syncona makes 'positive' operational and clinical progress in H1

(Sharecast News) - Healthcare company Syncona said on Thursday that it had delivered "positive operational and clinical progress" across its portfolio against a challenging macro backdrop in the six months ended 30 September.

IN BRIEF: Syncona notes investee Freeline's third-quarter loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes third-quarter results of investee Freeline Therapeutics Holdings PLC. Freeline's pretax loss in the third quarter that ended September 30 narrows to USD65.9 million from USD105.7 million a year prior. Research & development expenses decrease to USD53.6 million from USD70.8 million, and total operating expenses fall by 27% to USD78.6 million from USD108.0 million. Freeline continues to make no revenue. Freeline enters a definitive agreement to sell its chemistry, manufacturing & control focused German subsidiary and related intellectual property for USD25 million, with the sale being subject to price adjustments.

TRADING UPDATES: Zambeef expects profit jump; Mobile Streams wins deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

UK earnings, trading statements calendar - next 7 days

Syncona portfolio firm Autolus Therapeutics widens quarterly loss

(Alliance News) - Syncona Ltd on Thursday noted that its portfolio company Autolus Therapeutics PLC had widened its third quarter loss as it continued to progress its candidate pipeline.

Syncona to acquire retinal therapy firm Applied Genetic Technologies

(Alliance News) - Syncona Ltd on Monday it will expand its retinal gene therapy pipeline with the acquisition of a Florida-based biotechnology company.

Syncona to buy US biotech AGTC for $23.5m

(Sharecast News) - Healthcare group Syncona said on Monday that it has agreed to buy US biotechnology firm Applied Genetic Technologies Corporation (AGTC) for around $23.5m, or $0.34 per share, in cash.